Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

182 Views

241. PK/PD Studies: Saturday, 12:15 - 1:30 p.m.

Poster Session: PK/PD Studies

(2531) Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)

Saturday, October 14, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Sujata M. Bhavnani, PharmD; MS; FIDSA

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States

JH

Jeffrey P. Hammel, MS

Director
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
AR

Anthony J. Rinaldo, B.S.

Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
JS

Jennifer Smart, PhD

Sr. Microbiologist, Development
Basilea Pharmaceutica International Ltd
Allschwil, Basel-Landschaft, Switzerland
KL

Karine Litherland, Ph.D.

Basilea Pharmaceutica International Ltd
Allschwil,, Basel-Landschaft, Switzerland
Leonard R. Duncan, PhD (he/him/his)

Associate Director
JMI Laboratories
North Liberty, IA, United States
MJ

Mark E. Jones, PhD

Basilea Pharmaceutica International Ltd., Allschwil, Switzerland
Allschwil,, Basel-Landschaft, Switzerland
Marc Engelhardt, MD (he/him/his)

Dr.
Basilea Pharmaceutica International Ltd., Allschwil, Switzerland
Allschwil, Basel-Landschaft, Switzerland
PA

Paul G. Ambrose, PharmD; MS; FIDSA

President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
CR

Christopher M. Rubino, PharmD

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States